Avon Launches ‘Kiss Goodbye to Breast Cancer’ Campaign

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

NEW YORK-This month Avon Products, Inc. launches Kiss Goodbye to Breast Cancer, a marketing program that includes a fundraising lipstick, grassroots outreach through a Day of Commitment (September 25), gala awards to be held October 9, and celebrity support from singer Christina Aguilera and tennis players Serena and Venus Williams, among others.

NEW YORK—This month Avon Products, Inc. launches Kiss Goodbye to Breast Cancer, a marketing program that includes a fundraising lipstick, grassroots outreach through a Day of Commitment (September 25), gala awards to be held October 9, and celebrity support from singer Christina Aguilera and tennis players Serena and Venus Williams, among others.

The goal of the program is to raise additional funds and public awareness for the fight against breast cancer, building on the more than $140 million that Avon has already raised globally between 1992 to the end of 2000.

The lipsticks, priced at an affordable $4.00, include six shades in the Avon Ultra Color Rich Renewable formulation, named to capture the spirit of the crusade: Courageous Spirit, Crusade Pink, Faithful Heart, Inspirational Life, Strength, and Triumph.

The entire Avon Breast Cancer Crusade "pink ribbon" collection is available through Avon independent sales representatives by calling 1-800-FOR-AVON or visiting www.avoncrusade.com.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content